Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Atezolizumab Trial in Endometrial Cancer - AtTEnd
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-03-13
- Target Recruit Count
- 550
- Registration Number
- NCT03603184
- Locations
- 🇯🇵
Tohoku University Hospital, Miyagi, Japan
🇨🇭Universitätsspital, Zürich, Switzerland
🇨🇭Inselspital, Bern, Switzerland
Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-01-02
- Target Recruit Count
- 414
- Registration Number
- NCT03598270
- Locations
- 🇧🇪
Grand Hôpital de Charleroi, Charleroi, Belgium
🇪🇸Clinica Universidad de Navarra, Pamplona, Navarra, Spain
🇮🇹Istituto Europeo di Oncologia, Milano, Italy
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT03600701
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Fondazione Michelangelo
- Target Recruit Count
- 650
- Registration Number
- NCT03595592
- Locations
- 🇪🇸
MD Anderson Cancer Center, Madrid, Spain
🇪🇸Hospital Virgen de la Nieves, Granada, Spain
🇮🇹Ospedale Santa Maria della Misericordia, Udine, Italy
Study to Evaluate CCS1477 in Advanced Tumours
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- CellCentric Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT03568656
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT03566485
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT03563716
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States
🇺🇸SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States
🇺🇸SCRI Florida Cancer Specialists North; Research Office North Region., Saint Petersburg, Florida, United States
The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy
- First Posted Date
- 2018-06-18
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 358
- Registration Number
- NCT03559647
- Locations
- 🇩🇪
Dres. Michael Maasberg Marion Schmitz und Maria Theresia Keller, Mayen, Germany
🇩🇪Joh. Wesling Klinikum Minden; Klinik fuer Hämatologie und Onkologie, Minden, Germany
🇩🇪Friedrich-Ebert-Krankenhaus Klinik f. Hämatologie/ Onkologie u. Nephrologie, Neumunster, Germany
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix
- Conditions
- Interventions
- First Posted Date
- 2018-06-14
- Last Posted Date
- 2024-08-29
- Target Recruit Count
- 410
- Registration Number
- NCT03556839
- Locations
- 🇮🇹
Irccs S. Raffaele - Milano, Milano, Italy
🇯🇵Saitama medical university international medical center, Hidaka, Japan
🇯🇵Cancer Institute Hospital, Koto-Ku, Japan
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT03555149
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.